126 related articles for article (PubMed ID: 34917730)
1. Breast cancer risk in
Nañez A; Stram DA; Bethan Powell C; Garcia C
Gynecol Oncol Rep; 2022 Feb; 39():100899. PubMed ID: 34917730
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer surveillance following ovarian cancer in BRCA mutation carriers.
John CS; Fong A; Alban R; Gillen J; Moore KM; Walsh CS; Li AJ; Rimel BJ; Amersi F; Cass I
Gynecol Oncol; 2022 Jan; 164(1):202-207. PubMed ID: 34862065
[TBL] [Abstract][Full Text] [Related]
3. Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers.
Fong A; Cass I; John C; Gillen J; Moore KM; Gangi A; Walsh C; Li AJ; Rimel BJ; Karlan BY; Amersi F
Am Surg; 2020 Oct; 86(10):1243-1247. PubMed ID: 33106023
[No Abstract] [Full Text] [Related]
4. Breast cancer following ovarian cancer in BRCA mutation carriers.
Gangi A; Cass I; Paik D; Barmparas G; Karlan B; Dang C; Li A; Walsh C; Rimel BJ; Amersi FF
JAMA Surg; 2014 Dec; 149(12):1306-13. PubMed ID: 25372568
[TBL] [Abstract][Full Text] [Related]
5. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
McGee J; Giannakeas V; Karlan B; Lubinski J; Gronwald J; Rosen B; McLaughlin J; Risch H; Sun P; Foulkes WD; Neuhausen SL; Kotsopoulos J; Narod SA;
Gynecol Oncol; 2017 May; 145(2):346-351. PubMed ID: 28314588
[TBL] [Abstract][Full Text] [Related]
6. Clinical breast exam contribution to breast cancer diagnosis in BRCA mutation carriers vs. average to intermediate risk women.
Menes TS; Zippel D; Sklair-Levy M; Friedman E; Bernstein-Molho R; Faermann R; Madorsky Feldman D
Breast Cancer Res Treat; 2024 May; ():. PubMed ID: 38797791
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).
Artioli G; Giannone G; Valabrega G; Maggiorotto F; Genta S; Pignata S; Lorusso D; Cormio G; Scalone S; Nicoletto MO; Greco F; Rossi E; Spagnoletti I; De Giorgi U; Orditura M; Mosconi AM; Kardhashi A; Bogliolo S; Borgato L
Gynecol Oncol; 2021 Jun; 161(3):755-761. PubMed ID: 33888336
[TBL] [Abstract][Full Text] [Related]
8. Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain).
Ruiz de Sabando A; Urrutia Lafuente E; García-Amigot F; Alonso Sánchez A; Morales Garofalo L; Moreno S; Ardanaz E; Ramos-Arroyo MA
BMC Cancer; 2019 Nov; 19(1):1145. PubMed ID: 31771539
[TBL] [Abstract][Full Text] [Related]
9. Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.
Helpman L; Zidan O; Friedman E; Kalfon S; Perri T; Ben-Baruch G; Korach J
J Gynecol Oncol; 2017 Sep; 28(5):e61. PubMed ID: 28657222
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of breast screening strategies in a high risk breast and ovarian cancer clinic.
Knisely AT; Stewart ME; Garcia C; Thomas MH; Modesitt SC; Ring KL
Gynecol Oncol Rep; 2020 Aug; 33():100587. PubMed ID: 32490124
[TBL] [Abstract][Full Text] [Related]
11. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
12. Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer.
Domchek SM; Jhaveri K; Patil S; Stopfer JE; Hudis C; Powers J; Stadler Z; Goldstein L; Kauff N; Khasraw M; Offit K; Nathanson KL; Robson M
Cancer; 2013 Apr; 119(7):1344-8. PubMed ID: 23165893
[TBL] [Abstract][Full Text] [Related]
13. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
14. Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer.
Straub MM; Podoll MB; David SN; Wiesner GL; Desouki MM
Ann Diagn Pathol; 2018 Oct; 36():28-30. PubMed ID: 30055521
[TBL] [Abstract][Full Text] [Related]
15. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers.
Grindedal EM; Heramb C; Karsrud I; Ariansen SL; Mæhle L; Undlien DE; Norum J; Schlichting E
BMC Cancer; 2017 Jun; 17(1):438. PubMed ID: 28637432
[TBL] [Abstract][Full Text] [Related]
16. Germline and Somatic
You Y; Li L; Lu J; Wu H; Wang J; Gao J; Wu M; Liang Z
Front Oncol; 2020; 10():295. PubMed ID: 32211327
[No Abstract] [Full Text] [Related]
17. Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model.
Hoskins P; Eccleston A; Hurry M; Dyer M
Gynecol Oncol; 2019 Apr; 153(1):87-91. PubMed ID: 30704745
[TBL] [Abstract][Full Text] [Related]
18. Long-term mortality among women with epithelial ovarian cancer: a population-based study in British Columbia, Canada.
Arora N; Talhouk A; McAlpine JN; Law MR; Hanley GE
BMC Cancer; 2018 Oct; 18(1):1039. PubMed ID: 30359249
[TBL] [Abstract][Full Text] [Related]
19. Risk management options elected by women after testing positive for a BRCA mutation.
Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
